Cargando…

The relative clinical impact of sublingual immunotherapy with carbamylated monomeric allergoids on allergic respiratory symptoms

Detalles Bibliográficos
Autores principales:	Compalati, Enrico, Mistrello, Gianni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406506/ http://dx.doi.org/10.1186/1939-4551-8-S1-A37

Ejemplares similares

Safety of injective immunotherapy with monomeric carbamylated allergoid given to pediatric patients with allergic rhinitis with/without asthma due to house dust mite
por: Compalati, Enrico, et al.
Publicado: (2015)

Peripheral effector memory regulatory T cells are incremented and functionally enhanced in successful mite monomeric allergoid sublingual immunotherapy
por: Petrarca, Claudia, et al.
Publicado: (2020)

Sublingual immunotherapy with a carbamylated monomeric allergoidin cat-allergic patients suffering from rhinoconjunctivitis and/or allergic asthma. A multicenter, cross-sectional survey
por: Hauswald, Bettina
Publicado: (2015)

Poster 1000: Efficacy and safety of specific sublingual immunotherapy with carbamylated allergoid tablets of ragweed pollen: a dose-ranging study
por: Compalati, Enrico, et al.
Publicado: (2014)

11 Efficacy and Tolerability of HDM Injective Immunotherapy With Monomeric Allergoid
por: Compalati, Enrico, et al.
Publicado: (2012)

Real-Life Effectiveness of Subcutaneous Immune Therapy with Carbamylated Monomeric Allergoids on Mite, Grass, and Pellitory Respiratory Allergy: A Retrospective Study
por: Di Gioacchino, Mario, et al.
Publicado: (2022)

A 12‐week DBPC dose‐finding study with sublingual monomeric allergoid tablets in house dust mite‐allergic patients
por: Hüser, C., et al.
Publicado: (2016)

Allergen-Specific Immunotherapy with Monomeric Allergoid in a Mouse Model of Atopic Dermatitis
por: Shershakova, Nadezda, et al.
Publicado: (2015)

Sublingual or Subcutaneous immunotherapy for Seasonal Allergic Rhinitis (AR): an indirect analysis of efficacy, safety and cost
por: Dranitsaris, George, et al.
Publicado: (2014)

First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy
por: Nieto, Antonio, et al.
Publicado: (2022)

Sublingual immunotherapy: time to reconsider compliance and adherence
por: Eberle, Peter Friedrich
Publicado: (2015)

The effect of carbamylation on the functionality of high-density lipoprotein
por: Holzer, Michael, et al.
Publicado: (2009)

Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper
por: Passalacqua, Giovanni, et al.
Publicado: (2010)

The efficacy and safety of the short ragweed sublingual immunotherapy tablet MK-3641 is similar in asthmatic and nonasthmatic subjects treated for allergic rhinitis with/without conjunctivitis
por: Maloney, Jennifer, et al.
Publicado: (2014)

Immunotherapy – 2072. Therapeutic effect and higher safety profile for allergic asthma in Cuban patients with sublingual immunmotherapy using tropical domestic mite allergen vaccines
por: Almarales, Raúl Lázaro Castro, et al.
Publicado: (2013)

Assessment of stability and compatibility of dermatophagoides and blomia allergen mixture for sublingual immunotherapy
por: Morejón, Maytee Mateo, et al.
Publicado: (2015)

Sublingual immunotherapy in allergic rhinitis
por: Han, Doo Hee, et al.
Publicado: (2011)

Allergen specific sublingual immunotherapy (ASSIT) reduces Il-4 and enhances interferon-gamma intracellular expression by Cd8+ T-cells in perenneal allergic rhinitis (Par)
por: Farag – Mahmod, Farag I, et al.
Publicado: (2012)

The effect of the ragweed sublingual immunotherapy tablet MK-3641 on rescue medication use
por: Gawchik, Sandra, et al.
Publicado: (2014)

Efficacy of short-ragweed sublingual immunotherapy tablet MK-3641 in monosensitized and polysensitized subjects
por: Bernstein, David I, et al.
Publicado: (2014)

Immunotherapy – 2074. Tolerability of sublingual immunotherapy with tropical mite allergen vaccines using different dosing schedules in asthmatic children
por: Almarales, Raúl Lázaro Castro, et al.
Publicado: (2013)

Immunotherapy – 2082. Long term prevention of asthma and rhinitis in children with atopic dermatitis four year after discontinuation of sublingual immunotherapy
por: Passalacqua, Giovanni, et al.
Publicado: (2013)

Efficacy and safety of MK-7243: a grass allergy sublingual immunotherapy tablet evaluated in Canadian adults and children
por: Hébert, Jacques, et al.
Publicado: (2014)

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children
por: Tsabouri, Sophia, et al.
Publicado: (2017)

Immunotherapy – 2077. Allergen specific immunotherapy in allergic conjuntivitis due to dust mite
por: Pawar, Sanjay
Publicado: (2013)

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany
por: Verheggen, Bram G, et al.
Publicado: (2015)

Safety of specific subcutaneous immunotherapy in patients with allergic rhinitis
por: Da Fonseca, Mario Henrique Almeida, et al.
Publicado: (2015)

Corrigendum: Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children
por: Tsabouri, Sophia, et al.
Publicado: (2017)

Efficacy of Sublingual Immunotherapy versus Subcutaneous Injection Immunotherapy in Allergic Patients
por: Saporta, Diego
Publicado: (2012)

Efficacy and safety of standardized short ragweed sublingual immunotherapy tablet (SLIT-T) treatment in Canadian subjects with ragweed pollen-induced rhinitis with or without conjunctivitis
por: Blaiss, Michael, et al.
Publicado: (2014)

Safety of sublingual immunotherapy for asthma with standardized house dust mite vaccines in a tropical setting: Results of a nation-wide pharmacovigilance study
por: Morejón, Maytee Mateo, et al.
Publicado: (2015)

Allied health – 3007. The biomarker of sublingual immune therapy
por: Sakashita, Masafumi, et al.
Publicado: (2013)

Administration and burden of subcutaneous immunotherapy for allergic rhinitis in clinical practice in Canada
por: Blume, Steven W, et al.
Publicado: (2014)

Efficiacy of injection specific immunotherapy for grass pollen seasonal allergic rhinitis
por: Wasilewska, Eliza, et al.
Publicado: (2015)

Subcutaneous allergen immunotherapy with dermatophagoides pteronyssinus in patient with local allergic rhinitis
por: Rondon, Carmen, et al.
Publicado: (2015)

Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice
por: Petrarca, Claudia, et al.
Publicado: (2016)

Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite
por: Barberi, Salvatore, et al.
Publicado: (2015)

The relationship between sublingual immunotherapy for allergic rhinitis and the risk of symptoms in patients with COVID-19 infection
por: Zhang, Shipeng, et al.
Publicado: (2023)

Twenty years’ observation of subcutaneous pollen allergoid immunotherapy efficacy in adults
por: Bożek, Andrzej, et al.
Publicado: (2017)

10 Seasonal Versus Symptom-based Evaluation of a Depigmented Grass-Birch Allergoid
por: Pfaar, Oliver, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e5vaho1p730l2c9j0okfcgaggf